Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in OncologyWilliam J. Gradishar, Rashmi Kumar|Journal of the National Comprehensive Cancer Network|2020Cited by 1.6k
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021Harold J. Burstein, Binghe Xu, Peter Dubsky et al.|Annals of Oncology|2021Cited by 799
Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023Giuseppe Curigliano, B. Xu, Marleen Kok et al.|Annals of Oncology|2023Cited by 218
A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial.Kevin Kalinsky, Dawn L. Hershman, Melissa Accordino et al.|Journal of Clinical Oncology|2022Cited by 73
Dynamic Glycoprotein Hyposialylation Promotes Chemotherapy Evasion and Metastatic Seeding of Quiescent Circulating Tumor Cell Clusters in Breast CancerNurmaa K. Dashzeveg, Huiping Liu, Yuzhi Jia et al.|Cancer Discovery|2023Cited by 57